PL3512537T3 - Immunoterapia limfocytami t - Google Patents

Immunoterapia limfocytami t

Info

Publication number
PL3512537T3
PL3512537T3 PL16769929.7T PL16769929T PL3512537T3 PL 3512537 T3 PL3512537 T3 PL 3512537T3 PL 16769929 T PL16769929 T PL 16769929T PL 3512537 T3 PL3512537 T3 PL 3512537T3
Authority
PL
Poland
Prior art keywords
cell immunotherapy
immunotherapy
cell
Prior art date
Application number
PL16769929.7T
Other languages
English (en)
Inventor
Di YU
Magnus Essand
Chuan Jin
Mohanraj RAMACHANDRAN
Jing Ma
Original Assignee
Elicera Therapeutics Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elicera Therapeutics Ab filed Critical Elicera Therapeutics Ab
Publication of PL3512537T3 publication Critical patent/PL3512537T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/205—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Campylobacter (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PL16769929.7T 2016-09-15 2016-09-15 Immunoterapia limfocytami t PL3512537T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16769929.7A EP3512537B1 (en) 2016-09-15 2016-09-15 T-cell immunotherapy
PCT/EP2016/071775 WO2018050225A1 (en) 2016-09-15 2016-09-15 T-cell immunotherapy

Publications (1)

Publication Number Publication Date
PL3512537T3 true PL3512537T3 (pl) 2024-02-26

Family

ID=56979541

Family Applications (1)

Application Number Title Priority Date Filing Date
PL16769929.7T PL3512537T3 (pl) 2016-09-15 2016-09-15 Immunoterapia limfocytami t

Country Status (6)

Country Link
US (2) US20190209615A1 (pl)
EP (1) EP3512537B1 (pl)
CN (1) CN110225760B (pl)
ES (1) ES2964694T3 (pl)
PL (1) PL3512537T3 (pl)
WO (1) WO2018050225A1 (pl)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201713078D0 (en) 2017-08-15 2017-09-27 Adaptimmune Ltd T Cell Modification
WO2019199689A1 (en) * 2018-04-09 2019-10-17 The Trustees Of The University Of Pennsylvania Methods and compositions comprising a viral vector for expression of a transgene and an effector
US12359208B2 (en) 2020-04-15 2025-07-15 California Institute Of Technology Thermal control of T-cell immunotherapy through molecular and physical actuation
CN112226408B (zh) * 2020-09-30 2024-04-02 西北农林科技大学 一种猪病原或外源性蛋白特异性抗原肽筛选和鉴定的方法
CN112285347B (zh) * 2020-09-30 2023-12-22 西北农林科技大学 一种猪血清样中病原抗体elisa检测试剂盒
WO2023010118A1 (en) * 2021-07-29 2023-02-02 Vor Biopharma Inc. Nfat-responsive reporter systems for assessing chimeric antigen receptor activation and methods of making and using the same
CN113402620B (zh) * 2021-07-30 2021-12-10 中山大学 细胞因子联合嵌合抗原受体的融合蛋白及其应用
CN113402621B (zh) * 2021-08-02 2021-12-10 中山大学 含有嵌合抗原受体的融合蛋白及其应用
CN115980345A (zh) * 2022-08-30 2023-04-18 中国疾病预防控制中心传染病预防控制所 一种检测幽门螺旋杆菌的方法与应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1279404A1 (en) * 2001-07-26 2003-01-29 Istituto Superiore di Sanità Use of HIV-1 tat, fragments or derivatives thereof, to target or to activate antigen-presenting cells, to deliver cargo molecules for vaccination or to treat other diseases
ATE431156T1 (de) * 2005-09-23 2009-05-15 Prete Gianfranco Del Verwendung des neutrophil-activating-protein von helicobacter pylori und/oder teile davon als adjuvant für die induktion einer t-helper type 1 (th1) immunantwort
CN100579578C (zh) * 2006-07-20 2010-01-13 中国人民解放军第三军医大学 幽门螺杆菌抗原重组疫苗
WO2013120497A1 (en) * 2012-02-15 2013-08-22 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein
CN103990121B (zh) * 2013-12-06 2015-07-08 上海联合赛尔生物工程有限公司 抗原嵌合体、抗原组合物、疫苗及其制备方法和试剂盒
CN103923935B (zh) * 2014-04-22 2016-05-25 郑州大学 sIL-4R-NAP融合基因
US11382963B2 (en) * 2015-01-12 2022-07-12 Pieris Pharmaceuticals Gmbh Engineered T cells and uses therefor
KR102637610B1 (ko) * 2016-08-23 2024-02-19 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 단백질용해 절단가능한 키메라 폴리펩타이드 및 이의 사용 방법
US12479890B2 (en) * 2019-04-26 2025-11-25 The University Of North Carolina At Chapel Hill Chimeric antigen receptor constructs and their use in CAR-T cells

Also Published As

Publication number Publication date
US20260049119A1 (en) 2026-02-19
CN110225760A (zh) 2019-09-10
EP3512537C0 (en) 2023-11-01
WO2018050225A1 (en) 2018-03-22
US20190209615A1 (en) 2019-07-11
CN110225760B (zh) 2023-11-07
EP3512537A1 (en) 2019-07-24
ES2964694T3 (es) 2024-04-09
EP3512537B1 (en) 2023-11-01

Similar Documents

Publication Publication Date Title
ZA202005298B (en) Combination tumor immunotherapy
AU365267S (en) Ring
TWD174459S (zh) 戒指
GB201622033D0 (en) No details
PL3188641T3 (pl) Zespół utrzymujący
EP3215182A4 (en) Combination immunotherapy
PT3452507T (pt) Imunoterapia anti-tau
EP3160497A4 (en) Conjugates for immunotherapy
EP3512537C0 (en) T-CELL IMMUNOTHERAPY
PL3186160T3 (pl) Obejma zaciskowa
GB201702043D0 (en) No details
GB201709809D0 (en) No details
GB201415044D0 (en) Clamp
GB201603056D0 (en) Ring clip
GB201419210D0 (en) Clamp assembly
PL3094345T3 (pl) Immunoterapia oparta na liposomach
GB201703185D0 (en) No details
PL3450811T3 (pl) Opaska zaciskowa
GB201702268D0 (en) No details available
PL2975274T3 (pl) Układ zaciskowy
GB201406428D0 (en) Clamp
GB201709361D0 (en) No details
EP3228877A4 (en) Clamping band
GB201702267D0 (en) No details available
GB201604702D0 (en) Clamp